At 11.3% CAGR, Recombinant Vaccines Market Size [2021-2028] | is Expected to Reach USD 25.32 Billion

NEXT STORY
Matinas BioPharma Announces Unanimous DSMB Approval to Progress into Fourth and Final Cohort of Patients in the EnACT Trial of MAT2203 (Oral Amphotericin B) for the Treatment of Cryptococcal Meningitis
PREV STORY
G1 Therapeutics Announces Expansion of COSELA™ (Trilaciclib) Sales Force
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Emergent BioSolutions Receives Health Canada Approval for Botulism Antitoxin

GAITHERSBURG, Md., Dec. 12, 2016 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced ...

author_avatar
NASDAQ Market News

eFFECTOR Initiates Dosing of eFT508 (tomivosertib) in a Phase 2 Add-on (CPI-A) Trial in Combination with Checkpoint Inhibitors to Treat Patients with Insufficient Response to Checkpoint Inhibitors Alone

SAN DIEGO, July 27, 2018 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc., a leader in ...

author_avatar
NASDAQ Market News

Elicio Therapeutics Announces Virtual Presentation of Data on its Amphiphile-CpG Adjuvant at the Vaccines Summit 2021

author_avatar
NASDAQ Market News